Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 2.55B +35.3% |
| Revenue (ttm) | 535.08M +129.0% |
| Net Income | -48.27M |
| EPS | -1.13 |
| Shares Out | 43.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 370,081 |
| Open | 60.86 |
| Previous Close | 60.34 |
| Day's Range | 58.80 - 62.50 |
| 52-Week Range | 38.51 - 85.25 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 94.11 (+58.76%) |
| Earnings Date | May 6, 2026 |
About Hatton National Bank
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $94.11, which is an increase of 58.76% from the latest price.
News
Tarsus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
XDEMVY has achieved rapid adoption and strong revenue growth, with peak sales guidance raised to over $2 billion due to expanded prescriber base and effective DTC campaigns. The company is advancing its pipeline in ocular rosacea and Lyme disease, while maintaining a robust commercial infrastructure and monitoring profitability opportunities.
Tarsus Pharmaceuticals Transcript: 46th Annual William Blair Growth Stock Conference
XDEMVY continues strong commercial growth with expanded DTC campaigns and robust reimbursement, while new key account leaders and clinical studies drive deeper market penetration. Pipeline programs for ocular rosacea and Lyme disease are advancing, with pivotal data expected in 2027.
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals Transcript: Stifel 2026 Virtual Ophthalmology Forum
XDEMVY has achieved strong adoption with over 20,000 prescribers and 500,000 patients treated, driving a raised peak sales outlook to $2 billion. Pipeline programs in ocular rosacea and Lyme disease prevention are advancing, with robust reimbursement and a solid cash position supporting continued growth.
Tarsus Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
XDEMVY has driven strong revenue growth and broad prescriber adoption, supported by effective DTC campaigns and a robust sales strategy. Pipeline programs in ocular rosacea and Lyme disease offer significant future potential, while international expansion is being evaluated amid policy considerations.
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but of...
Tarsus Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
XDEMVY’s commercial momentum continues with strong Q1 results, expanding prescriber base, and improved DTC ROI. Pipeline assets in ocular rosacea and Lyme disease advance, with strategic focus on operating leverage and payer value. Guidance and market opportunity remain robust.
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
Reports Q1 revenue $162.05M, consensus $148.73M. “XDEMVY is driving a fundamental shift in how Demodex blepharitis is diagnosed and treated,” said Bobak Azamian, Chief Executive Officer and Chairman o...
Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw XDEMVY net product sales rise over 85% year-over-year to $145 million, with strong physician adoption and expanding retreatment rates. Full-year guidance of $670–$700 million in sales was reaffirmed, and pipeline programs for Lyme disease and ocular rosacea advanced on schedule.
Tarsus Pharmaceuticals Earnings release: Q1 2026
Tarsus Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Tarsus Pharmaceuticals Quarterly report: Q1 2026
Tarsus Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
Tarsus Pharmaceuticals Slides: Q1 2026
Tarsus Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product s...
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.
Tarsus Pharmaceuticals Proxy statement: Proxy filing
Tarsus Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Tarsus Pharmaceuticals Proxy statement: Proxy filing
Tarsus Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Tarsus Pharmaceuticals (TARS) with an Outperform rating with a price target of $98, down from $105. The firm views Tarsus as a successful category-creation commercial b...
Tarsus Pharmaceuticals doses first participant in TP-05 trial
Tarsus Pharmaceuticals (TARS) announced that the first participant has been dosed in the Phase 2 clinical trial evaluating TP-05, a novel investigational oral therapy designed to potentially prevent L...
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evalua...
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $101 from $100 and keeps an Outperform rating on the shares after the company announced its…
Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
Tarsus Pharmaceuticals (TARS) announced that a $15M milestone payment due Tarsus has been achieved following regulatory approval of TP-03, or lotilaner ophthalmic solution, 0.25% by the National Medic...
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ap...
Tarsus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
XDEMVY's launch has exceeded expectations, with rapid revenue growth, broad payer coverage, and strong prescriber engagement. The addressable market remains largely untapped, and DTC campaigns are expanding awareness. Peak sales guidance has doubled to $2B+, with a robust pipeline and strong financials supporting future growth.
Tarsus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is rapidly expanding in eye care, with XDEMVY achieving $450M in revenue and targeting $2B+ peak sales. Pipeline assets TP-04 and TP-05 address large unmet needs, with key data expected in 2027. Strategic investments in DTC and sales force expansion support continued growth.
Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $105 from $95 and keeps an Outperform rating on the shares following quarterly results. Importa...